FDA Rejects “Not Approvable” Letters, Clarifies Efficacy Supplement
This article was originally published in The Tan Sheet
Executive Summary
FDA says industry concerns about the implied finality of "not approvable" letters led it to change how it responds to drug applications
You may also be interested in...
Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application
FDA indicated to Schering-Plough that the firm's Rx-to-OTC switch application for the proton pump inhibitor Zegerid is not ready for approval
“Complete Response” Reg Proposes Deficiency Letter For Withdrawn NDAs
The definition of an efficacy supplement, which covers Rx-to-OTC switch applications, would be written into regulation for the first time under a new proposed rule issued by FDA
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC